Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It stands out in its class due to its unique excretion pathway.

Mechanism of Action
Linagliptin competitively and reversibly binds to the DPP-4 enzyme, preventing the breakdown of incretin hormones (GLP-1 and GIP). This action increases the concentration of active incretins, stimulating insulin release in a glucose-dependent manner and reducing glucagon levels in the circulation.

Dosage and Administration
The standard dose is 5 mg once daily, which can be taken with or without food. A key advantage of linagliptin is that no dose adjustment is required for patients with renal or hepatic impairment, as it is primarily excreted un-metabolized via the enterohepatic system.

Side Effects
It is generally well-tolerated. The most frequently reported adverse reactions are nasopharyngitis, diarrhea, and cough. Hypoglycemia risk is low when used as monotherapy but increases if combined with insulin or sulfonylureas. There have been post-marketing reports of acute pancreatitis.

Contraindications
Linagliptin is contraindicated in patients with a known hypersensitivity to the drug. It should not be used to treat type 1 diabetes or diabetic ketoacidosis.

Pregnancy and Lactation
As with other DPP-4 inhibitors, there are no adequate and well-controlled studies in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution is advised during breastfeeding.